| Current Price | $72.50 | Mkt Cap | $4.1B |
|---|---|---|---|
| Open | $73.92 | P/E Ratio | 0.00 |
| Prev. Close | $73.68 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $71.42 - $74.35 | Volume | 2,260,049 |
| 52-Wk Range | $71.42 - $163.43 | Avg. Daily Vol. | 1,003,070 |
| Current Price | $72.50 | Mkt Cap | $4.1B |
|---|---|---|---|
| Open | $73.92 | P/E Ratio | 0.00 |
| Prev. Close | $73.68 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $71.42 - $74.35 | Volume | 2,260,049 |
| 52-Wk Range | $71.42 - $163.43 | Avg. Daily Vol. | 1,003,070 |
The best Bull and Bear pitches based on recency and number of recommendations.
I am very impressed with Nick Leschly. You can watch his Ted Talk here:https://www.youtube.com/watch?v=Ez560GnkSrE
Selling for a while after the huge drop today, good for a trade
Read the most recent pitches from players about BLUE.
Recs
SurfingCabarete
(24.86)
Submitted: 7/9/2019 12:18:18 PM :
Start Price:
$131.71
NASDAQ:BLUE Score:
-49.74
another bet on gene editing
Recs
jbonefish
(54.50)
Submitted: 6/14/2019 10:51:02 PM :
Start Price:
$118.05
NASDAQ:BLUE Score:
-46.00
In the “age of miracles” Bluebird is out in front in applying the science and focused on the types of diseases (single gene mutations) that are most likely to result in breakthrough treatments initially. Rather than being a good moonshot story, BLUE is doing the work that will solve problems for patients - that is a better recipe for long term financial success than a good story.
Recs
MarkFitzFool
(41.53)
Submitted: 5/11/2019 12:39:01 PM :
Start Price:
$132.45
NASDAQ:BLUE Score:
-55.37
$BLUE is a leader in the new wave, the future, of personalized genomic therapies based on both gene editing and immunotherapy. They're ahead of Edits when it comes to bringing their Beta-Thalassemia and Sickle Cell Disease therapies to market. Mark my words, they will be the first to market with those therapies (although there is room for several players in the space). They have impressive partnerships with Regeneron, Celgene, Boston Children's Hospital, Seattle Children's Hospital, etc. I know from speaking to some senior scientists at the company, that they plan to file FDA approval for at least four candidate therapies within the next two years. Beta-Thalassemia approval in the EU will likely come first. Is it a risky investment? Yes, a bit, as is the nature of virtually all developmental and pre-clinical stage biotechs, but they are a true leader, and I don't see them going away or failing anytime soon.
Find the members with the highest scoring picks in BLUE.
DoubleBagel (33.19) Score: +669.10
The Score Leader is the player with the highest score across all their picks in BLUE.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| portefeuille12 | 29.24 | 4/16/2014 |
|
5Y | $19.11 | +279.38% | +67.46% | +211.92 | 0 Comment | |
| portefeuille2 | 98.78 |
|
|
5Y | $20.74 | +249.57% | +70.96% | +178.60 | 0 Comment | |
| portefeuille3 | 97.02 | 4/11/2014 |
|
5Y | $20.74 | +249.57% | +71.10% | +178.46 | 0 Comment | |
| johninmadison | 81.66 | 4/7/2014 |
|
5Y | $21.07 | +244.09% | +67.28% | +176.81 | 0 Comment | |
|
efarev | 98.22 | 11/5/2013 |
|
5Y | $20.53 | +253.14% | +76.67% | +176.47 | 0 Comment |
| portefeuille6 | 99.36 | 4/11/2014 |
|
5Y | $20.91 | +246.72% | +71.33% | +175.39 | 0 Comment | |
| HoosierDoozer | < 20 | 2/5/2014 |
|
5Y | $20.84 | +247.89% | +77.92% | +169.97 | 0 Comment | |
| portefeuille | 98.35 | 4/8/2014 |
|
5Y | $21.44 | +238.15% | +68.70% | +169.45 | 1 Comment | |
| jack0071 | 71.07 | 1/8/2014 |
|
5Y | $21.47 | +237.68% | +69.52% | +168.16 | 0 Comment | |
| jtothes | 72.84 | 2/14/2014 |
|
3Y | $21.88 | +231.35% | +70.08% | +161.27 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
